Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Gracell Acquires CLDN18.2 Antibodies for CAR-T Candidates

publication date: Aug 16, 2021

Gracell Bio, a Suzhou CAR-T company, acquired rights to FutureGen's CLDN18.2 antibodies, which it will use to develop novel immune cell therapies for solid tumors. CLDN18.2 is a tumor biomarker that is overexpressed in a variety of tumors, including gastric or gastroesophageal junction cancers, pancreatic cancers and esophageal cancers. Gracell is developing several technologies to improve the efficacy and lower the cost of CAR-T therapies. It will make upfront, milestone and royalty payments to Palo Alto's FutureGen. More details....

Stock Symbols: (NSDQ: GRCL)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.